You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-glucagon receptor antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hyperglycemia Drug Induced Trial in Durham (REMD-477)

Terminated
  • Hyperglycemia Drug Induced
  • REMD-477
  • Durham, North Carolina
    Duke University Medical Center
Jun 9, 2021

Healthy Trial in Qingdao (VDJ001, Placebo)

Completed
  • Healthy
  • Qingdao, Shandong, China
    the Affliated Hospital of Qingdao University
Aug 30, 2023

Hyperglycemia Drug Induced Trial in Durham (REMD-477)

Terminated
  • Hyperglycemia Drug Induced
  • REMD-477
  • Durham, North Carolina
    Duke University Medical Center
Nov 4, 2022

Idiopathic Multicentric Castleman's Disease Trial in Beijing, Chengdu (Recombinant Humanized Anti-interleukin-6 Receptor

Recruiting
  • Idiopathic Multicentric Castleman's Disease
  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg
  • +2 more
  • Beijing, China
  • +2 more
Apr 26, 2022

Psycho-social Impact of Anti-NMDAR Encephalitis

Not yet recruiting
  • NMDAR Antibody-associated Auto-immune Encephalitis
  • standardized and validated surveys
  • Bron, France
    Centre de référence des syndromes neurologiques paranéoplasiques
Jul 13, 2023

Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS) Trial in Marseille (blood samples)

Completed
  • Axial Spondyloarthritis (axSpA)
  • Ankylosing Spondylitis (AS)
  • blood samples
  • Marseille, France
    Assistance Publique Hopitaux de Marseille
Aug 31, 2022

Anti-obesity Pharmacotherapy and Inflammation

Not yet recruiting
  • Obesity
  • Liraglutide or Semaglutide
  • Phentermine-Topiramate combination
  • New Orleans, Louisiana
  • +1 more
Mar 3, 2023

Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,

Not yet recruiting
  • Idiopathic Inflammatory Myopathies
  • +3 more
  • (no location specified)
Nov 21, 2023

Migraine Disorders, Chronic Migraine, Episodic Migraine Trial in Pavia (Monoclonal antibody targeting the CGRP pathway (ligand

Recruiting
  • Migraine Disorders
  • +2 more
  • Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
  • Pavia, Italy
    Headache Science & Neurorehabilitation Center
Nov 23, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer Trial in United States (STRO-002, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Tampa, Florida
  • +5 more
Aug 1, 2022

Moderate to Severe Active Rheumatoid Arthritis Trial in Beijing (HS628+MTX, Actemra +MTX)

Completed
  • Moderate to Severe Active Rheumatoid Arthritis
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 14, 2023

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Active, not recruiting
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +16 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,

Active, not recruiting
  • Estrogen Receptor Negative
  • +15 more
  • Bellevue, Nebraska
  • +3 more
Nov 30, 2022

Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR

Not yet recruiting
  • Pericarditis
  • IL1RA Antibody Assay
  • suPAR Testing
  • Homburg, Germany
  • +8 more
Jun 22, 2023

MuSK Myasthenia Gravis Trial (MuSK-CAART)

Not yet recruiting
  • MuSK Myasthenia Gravis
  • MuSK-CAART
  • (no location specified)
Jul 5, 2022

Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity Trial in Glostrup, Odense (drug, dietary supplement,

Recruiting
  • Idiopathic Intracranial Hypertension
  • +5 more
  • Glostrup, Denmark
  • +1 more
Sep 7, 2023

Advanced/Metastatic Solid Tumors Trial in Frankston, Nedlands, Beijing (EMB07)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Frankston, Victoria, Australia
  • +2 more
Nov 3, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Graves Ophthalmopathy Trial in Italy (Tocilizumab 20 Mg/mL Intravenous Solution, MethylPREDNISolone Injectable Solution)

Recruiting
  • Graves Ophthalmopathy
  • Tocilizumab 20 Mg/mL Intravenous Solution
  • MethylPREDNISolone Injectable Solution
  • Milano, MI, Italy
  • +3 more
Aug 3, 2022

Healthy Volunteers Trial in Hannover (CSL324, Placebo)

Recruiting
  • Healthy Volunteers
  • Hannover, Germany
    Fraunhofer Institute for Toxicology and Experimental Medicine
Jan 28, 2023

Healthy Male Subjects Trial in Changsha (sintilimab (after the change), sintilimab (before the change))

Recruiting
  • Healthy Male Subjects
  • sintilimab (after the change)
  • sintilimab (before the change)
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Dec 5, 2022

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022